Do analysts recommend BTCY or ICCM?

IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,766.07%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is BTCY or ICCM more profitable?

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -441.60%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% IceCure Medical -441.60% -211.73% -119.13%

Do analysts rate FEMY or BTCY?

Femasys presently has a consensus target price of $106.67, indicating a potential upside of 2,628.05%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is FEMY or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to Femasys' net margin of -521.97%. Biotricity's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Biotricity -80.42% N/A -188.47%

Does the media favor FEMY or BTCY?

In the previous week, Femasys and Femasys both had 1 articles in the media. Femasys' average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biotricity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BTCY or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BTCY or OSRH?

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biotricity $12.06M 0.26 -$14.09M -$0.12 N/A OSR $2.91M 5.28 -$27.06M -$0.33 N/A

Is BTCY or OSRH more profitable?

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% OSR -363.26% -7.24% -5.41%

Do analysts prefer BTCY or SURG?

SurgePays has a consensus target price of $3.50, suggesting a potential upside of 1,083.63%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BTCY or SURG more profitable?

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% SurgePays -64.91% N/A -310.16%

Does the media refer more to BTCY or SURG?

In the previous week, SurgePays had 1 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Biotricity. SurgePays' average media sentiment score of 0.99 beat Biotricity's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biotricity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SurgePays 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BTCY or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,760.17%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Co-Diagnostics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BTCY or CODX more profitable?

Biotricity has a net margin of -80.42% compared to Co-Diagnostics' net margin of -6,760.63%. Biotricity's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media prefer BTCY or CODX?

In the previous week, Biotricity and Biotricity both had 1 articles in the media. Biotricity's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biotricity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biotricity (BTCY) Competitors

$0.11 +0.00 (+3.96%)

As of 10:48 AM Eastern

Compare

BTCY vs. ICCM, FEMY, OSRH, SURG, and CODX

Should you buy Biotricity stock or one of its competitors? MarketBeat compares Biotricity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biotricity include IceCure Medical (ICCM), Femasys (FEMY), OSR (OSRH), SurgePays (SURG), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.

How does Biotricity compare to IceCure Medical?

Biotricity (NASDAQ:BTCY) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,766.07%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -441.60%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
IceCure Medical	-441.60%	-211.73%	-119.13%

Biotricity has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, Biotricity had 1 more articles in the media than IceCure Medical. MarketBeat recorded 1 mentions for Biotricity and 0 mentions for IceCure Medical. Biotricity's average media sentiment score of 0.00 equaled IceCure Medical'saverage media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
IceCure Medical	Neutral

3.9% of Biotricity shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 1.6% of Biotricity shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biotricity has higher revenue and earnings than IceCure Medical. Biotricity is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.12	N/A
IceCure Medical	$3.38M	3.41	-$15.06M	-$7.21	N/A

Summary

Biotricity beats IceCure Medical on 9 of the 15 factors compared between the two stocks.

How does Biotricity compare to Femasys?

Femasys (NASDAQ:FEMY) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

65.3% of Femasys shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 1.6% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biotricity has a net margin of -80.42% compared to Femasys' net margin of -521.97%. Biotricity's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Biotricity	-80.42%	N/A	-188.47%

Femasys presently has a consensus target price of $106.67, indicating a potential upside of 2,628.05%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Femasys and Femasys both had 1 articles in the media. Femasys' average media sentiment score of 0.00 equaled Biotricity'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biotricity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Femasys has a beta of -2.13, indicating that its share price is 313% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Biotricity has higher revenue and earnings than Femasys. Biotricity is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	5.16	-$18.63M	-$5.40	N/A
Biotricity	$12.06M	0.26	-$14.09M	-$0.12	N/A

Summary

Femasys and Biotricity tied by winning 7 of the 14 factors compared between the two stocks.

How does Biotricity compare to OSR?

Biotricity (NASDAQ:BTCY) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Biotricity had 1 more articles in the media than OSR. MarketBeat recorded 1 mentions for Biotricity and 0 mentions for OSR. Biotricity's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
OSR	Neutral

3.9% of Biotricity shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 1.6% of Biotricity shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biotricity has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, OSR has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
OSR	-363.26%	-7.24%	-5.41%

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.12	N/A
OSR	$2.91M	5.28	-$27.06M	-$0.33	N/A

Summary

Biotricity beats OSR on 8 of the 13 factors compared between the two stocks.

How does Biotricity compare to SurgePays?

Biotricity (NASDAQ:BTCY) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

3.9% of Biotricity shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 1.6% of Biotricity shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SurgePays has a consensus target price of $3.50, suggesting a potential upside of 1,083.63%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
SurgePays	-64.91%	N/A	-310.16%

Biotricity has higher earnings, but lower revenue than SurgePays. Biotricity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.12	N/A
SurgePays	$56.96M	0.13	-$36.07M	-$1.94	N/A

Biotricity has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, SurgePays had 1 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for SurgePays and 1 mentions for Biotricity. SurgePays' average media sentiment score of 0.99 beat Biotricity's score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biotricity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SurgePays beats Biotricity on 9 of the 15 factors compared between the two stocks.

How does Biotricity compare to Co-Diagnostics?

Biotricity (NASDAQ:BTCY) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 1.6% of Biotricity shares are owned by insiders. Comparatively, 5.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Biotricity and Biotricity both had 1 articles in the media. Biotricity's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biotricity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biotricity has higher revenue and earnings than Co-Diagnostics. Biotricity is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.12	N/A
Co-Diagnostics	$620K	14.05	-$46.90M	-$15.77	N/A

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 2,760.17%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biotricity has a net margin of -80.42% compared to Co-Diagnostics' net margin of -6,760.63%. Biotricity's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

Biotricity has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.84, indicating that its share price is 184% more volatile than the broader market.

Summary

Co-Diagnostics beats Biotricity on 8 of the 14 factors compared between the two stocks.

Get Biotricity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTCY vs. The Competition

Export

Metric	Biotricity	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.15M	$38.94M	$6.81B	$12.41B
Dividend Yield	N/A	1.08%	2.67%	9.39%
P/E Ratio	-0.10	16.98	27.00	24.19
Price / Sales	0.26	26.05	517.85	93.08
Price / Cash	N/A	18.86	26.68	47.25
Price / Book	-0.08	9.22	10.67	6.26
Net Income	-$14.09M	-$17.39M	$3.60B	$331.76M
7 Day Performance	N/A	-1.82%	-0.37%	-1.10%
1 Month Performance	-8.77%	-2.58%	1.80%	-1.29%
1 Year Performance	-77.04%	-14.62%	25.50%	18.84%

Biotricity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTCY Biotricity	N/A	$0.11 +4.0%	N/A	-75.6%	$3.15M	$12.06M	N/A	40	News Coverage
ICCM IceCure Medical	2.3496 of 5 stars	$3.89 -4.9%	$62.70 +1,511.8%	-89.1%	$14.01M	$3.57M	N/A	60
FEMY Femasys	1.3965 of 5 stars	$3.85 -2.8%	$106.67 +2,670.6%	-81.4%	$11.96M	$2.38M	N/A	30	Gap Down Trading Halted
OSRH OSR	0.5916 of 5 stars	$0.33 +6.9%	N/A	-56.3%	$10.80M	$2.91M	N/A	N/A
SURG SurgePays	4.2598 of 5 stars	$0.40 -0.2%	$3.50 +775.0%	-89.0%	$10.07M	$62.37M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTCY) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biotricity (BTCY) Competitors

BTCY vs. ICCM, FEMY, OSRH, SURG, and CODX

How does Biotricity compare to IceCure Medical?

Summary

How does Biotricity compare to Femasys?

Summary

How does Biotricity compare to OSR?

Summary

How does Biotricity compare to SurgePays?

Summary

How does Biotricity compare to Co-Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biotricity (BTCY) Competitors

BTCY vs. ICCM, FEMY, OSRH, SURG, and CODX

How does Biotricity compare to IceCure Medical?

Do analysts recommend BTCY or ICCM?

Is BTCY or ICCM more profitable?

Which has more risk & volatility, BTCY or ICCM?

Does the media prefer BTCY or ICCM?

Do institutionals and insiders have more ownership in BTCY or ICCM?

Which has preferable valuation and earnings, BTCY or ICCM?

Summary

How does Biotricity compare to Femasys?

Do institutionals & insiders believe in FEMY or BTCY?

Is FEMY or BTCY more profitable?

Do analysts rate FEMY or BTCY?

Does the media favor FEMY or BTCY?

Which has more volatility and risk, FEMY or BTCY?

Which has better valuation & earnings, FEMY or BTCY?

Summary

How does Biotricity compare to OSR?

Does the media prefer BTCY or OSRH?

Do insiders and institutionals hold more shares of BTCY or OSRH?

Which has more volatility and risk, BTCY or OSRH?

Do analysts recommend BTCY or OSRH?

Is BTCY or OSRH more profitable?

Which has higher valuation and earnings, BTCY or OSRH?

Summary

How does Biotricity compare to SurgePays?

Do insiders & institutionals hold more shares of BTCY or SURG?

Do analysts prefer BTCY or SURG?

Is BTCY or SURG more profitable?

Which has higher earnings and valuation, BTCY or SURG?

Which has more risk and volatility, BTCY or SURG?

Does the media refer more to BTCY or SURG?

Summary

How does Biotricity compare to Co-Diagnostics?

Do insiders and institutionals have more ownership in BTCY or CODX?

Does the media prefer BTCY or CODX?

Which has stronger valuation & earnings, BTCY or CODX?

Do analysts prefer BTCY or CODX?

Is BTCY or CODX more profitable?

Which has more risk & volatility, BTCY or CODX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools